Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
Vaccines can be extremely cost-effective public health measures. Unfortunately the research and development (R&D) of novel vaccines is suffering from rising costs and declining success rates. Because many vaccines target low- and middle income markets (LMIC), output needs to be maintained at...
Main Authors: | Meta Roestenberg, Ingrid M. C. Kamerling, Saco J. de Visser |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fmed.2018.00297/full |
Similar Items
-
Corrigendum: Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
by: Meta Roestenberg, et al.
Published: (2019-02-01) -
Malaria Vaccine Development and How External Forces Shape It: An Overview
by: Veronique Lorenz, et al.
Published: (2014-06-01) -
Implementing new health interventions in developing countries: why do we lose a decade or more?
by: Brooks Alan, et al.
Published: (2012-08-01) -
The Delay in the Licensing of Protozoal Vaccines: A Comparative History
by: Clarisa Beatriz Palatnik-de-Sousa, et al.
Published: (2020-03-01) -
Challenges of Developing Novel Vaccines With Particular Global Health Importance
by: Penny M. Heaton
Published: (2020-10-01)